Comments
Laurus Labs Ltd has completed pre-approval inspection for an Active Pharmaceutical Ingredient (API) product manufactured at its Units 1 and 3, located at JN Pharma City, Parawada, Visakhapatnam, Andhra Pradesh, with three observations from the US Food and Drug Administration (US FDA).
According to the company, the observations“are procedural in nature, and no data integrity issues were observed in the inspection.”
The inspection was carried out from 18-21, November 2019.
Laurus Labs’ scrip lost 1.47 per cent on the Bombay Stock Exchange (BSE) on Thursday to end at Rs 334.30.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.